Compare Jones Lang LaSalle Inc (JLL) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Jones Lang LaSalle Inc trades at $303.6 (market cap $13.95B), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.74B). The key difference: Jones Lang LaSalle Inc is far larger — about 8× Nuvation Bio Inc. Class A Common Stock's market cap, and Jones Lang LaSalle Inc is more actively traded (457,462 versus 9,289,619). Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| JLL | NUVB | |
|---|---|---|
Market Cap | $13.95B | $1.74B |
Volume | 457,462 | 9,289,619 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $9.54 |
52-Week Low | $280.16 | $3.41 |
Typical Hold Time | 71 Days | 0 Days |
Enterprise Value | $16.71B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $296.66, down 2.29% today, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $5.26 beating expectations by 15%. Revenue growth accelerated to $26.12 billion in 2025, while net income margin improved to 3.64%. Recent acquisitions and financing deals demonstrate continued expansion in key markets.
The stock presents a compelling value opportunity with a P/E of 14.23 and P/S of 0.52 below industry averages. Analyst consensus targets $450.50, implying 52% upside potential. Key risks include real estate market cyclicality and execution challenges in global expansion. Strong cash flow generation and institutional buying support the bullish fundamental case despite near-term technical weakness.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
